MapLight Therapeutics, Inc. - 10-Q Filing

MapLight Therapeutics reports Q3 2025 financial results including research and development, general and administrative expenses, and updates on equity incentive plans.

SEC EDGAR ·

Tickers: $MPLT

Read the full article at SEC EDGAR

More Regulatory news